Presentation is loading. Please wait.

Presentation is loading. Please wait.

Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for.

Similar presentations


Presentation on theme: "Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for."— Presentation transcript:

1 The Cost of Medication Management in the Diabetic Patient By Paula Straub, RPh

2 Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for oral medications and non- insulin treatment options Discuss cost impact for insulin therapies

3 Diabetes Facts Nearly 86 million Americans have pre-diabetes and another 30 million have diabetes Overall cost to treat pre-diabetes and diabetes has escalated to $322 Billion As the number of cases increases, the cost of diabetes treatment and medications is rising Diabetes patients incur medical expenses 2.3 times higher than those without diabetes Significant increase in vital diabetes medications has occurred over the past few years, especially insulin therapy Managed Healthcare Executive-4/17. Advancements in Diabetes.

4 Treatment Goals Management of both hyperglycemia and risk factors
Individualized Approach

5 Important Factors for Best Therapeutic Pharmacologic Approach
Assessment of patient’s health and comorbid conditions Extent of A1C elevation Patient motivation Adherence-approach should be simple Cost Risk of Hypoglycemia Patient’s weight Patient’s age AACE/ACE Comprehensive Diabetes Mgmt Algorithm, 2017.

6 Factors Continued Ease of use
Safety impact of kidney, liver and liver disease Individual circumstances Formulary Restrictions Combination therapy usually required and should involve agents with complementary actions Monitoring requirements Other Adverse Effects AACE/ACE Comprehensive Diabetes Mgmt Algorithm, 2017.

7 Effectiveness of Therapy Evaluation
Evaluated frequently until stable using multiple criteria A1C SMBG records-fasting and post-prandial Documented and suspected hypoglycemia Potential adverse effects..i.e. weight gain, fluid retention, hepatic, renal or cardiac disease Comorbidities and concomitant drug administration American Diabetes Association-Diabetes Basics.

8 Oral Medications with Cost Analysis Biguanides
Metformin Metformin HCL(500mg, 850mg, 1000mg)-$4.00 list $4.00/60/30 days $10.00/180/90 days Metformin HCL ER 500mg-$4.00/60/30 days, $10.00/180/90days 750mg-$71.82, 1000mg-$124.95(Fortamet) Fortamet/Glumetza (generic)-Costly! 500mg ER-$421.69 500mg ER-$ , 750mg ER- $ ,1000mg ER-$ Walmart List, 1/2017. WAC. First Data. 2017

9 Sulfonylureas 1st Generation Chlorpropamide-Approximate cost/month-$20
Tolazamide-Approximate cost/month-$48 Tolbutamide-Approximate cost/month-$70 WAC. First Data. 2017

10 Sulfonylureas 2nd Generation Glimepiride
Drug Name Cost Glimepiride Walmart list $4.00/ 30 days, $10.00/ 90 days Glipizide $4.00/ 30 days, $10.00/ 90 days Glyburide Walmart list. 1/2017

11 Meglitinides Nateglinide (Starlix)- Approximate cost/month-$85
Repaglinide (Prandin)- Approximate cost/month- $50/Prandimet-$55 Repaglinide/Metformin (Prandimet)-Approximate cost/month- $65 WAC. First Data. 2017

12 TZDs Pioglitazone (Actos)-Approximate cost/month-$25; Alogliptin/Pioglitazone (Oseni)-$195 Avandia-Approximate cost/month-$115 WAC. First Data. 2017

13 DPP-4 Inhibitors Drug Name Cost Januvia/Janumet $381/$381
Onglyza/Kombiglyze XR $385/$485 Tradjenta/Jentadueto Nesina/Kazano $374/$399 WAC. First Data. 2017

14 SGLT2 Inhibitors (Canagliflozin)-Invokana-Approximate cost/month- $ With Metformin/Invokamet, XR-$ (Dapagliflozin)-Farxiga-Approximate cost/month- $ With Metformin/Xigduo XR-$ (Empagliflozin)-Jardiance-Approximate cost/month- $ With Linagliptin/Glyxambi-$ With Metformin-Synjardy, XR-$ WAC. First Data. 2017

15 Alpha-Glucosidase Inhibitors
Acarbose (Precose)-Approximate cost/month-$45 Miglitol (Glyset)-Approximate cost/month-$145 WAC. First Data, 2017.

16 Bile Acid Sequestrants
Colesevelam (Welchol)- Approximate cost/month-$470 WAC. First Data, 2017.

17 Cost Analysis for GLP1 Agonists
Drug Name Cost/Month Tanzeum $426.36 Trulicity $585 Byetta $574.01 Bydureon $570.32

18 Cost Analysis for GLP1 Agonists-Continued
Drug Name Cost/Month Victoza $612.78 Xultophy $850-$950 Adlyxin $600 Soliqua $740-$760 WAC. First Data. 2017

19 Cost Analysis for Rapid Acting Insulins
Humalog-100 units/ml: $254.80/10 ml vial; $414/5 of 3ml cartridge, $430.25/5 of 3ml Kwikpen 200units/ml: $393.60/2 of 3ml Kwikpen Novolog-$275.58/10 ml vial; $393.60/5 of 3ml Penfill, $532.20/5 of 3 ml Flexpen Apidra-$255.11/10 ml vial; $492.83/5 of 3ml Solostar Pen WAC. First Data

20 Short Acting Insulins Humulin R-$137.90/10 ml vial; $1379/20ml vial (U500); $514.56/2 of 3 ml Kwikpen (U-500) Novolin R-$137.70/ 10 ml vial WAC.First Data. 2017

21 Intermediate-Acting Insulins
Humulin N-$137.90/ 10 ml vial; $437.25/5 of 3ml Kwikpen Novolin N-$137.70/ 10 ml vial WAC. First Data. 2017

22 Approximate cost/month
Long Acting Insulins Drug Name Approximate cost/month Basaglar Kwikpen $316.80/pkg/5 of 3ml Lantus, Solostar (~$ vial) , (~$372.50/pkg/5 of 3ml) Levemir, Flextouch (~$269 vial) , (~$403.50/pkg/5 of 3ml) Toujeo Solostar (~$335.48/pkg/3 of 1.5ml) WAC. First Data

23 Ultra Long-Acting Insulins
Tresiba-$443.85/5 of 3ml Flextouch (100 unit/ml), $532.62/3 of 3ml Flextouch (200 unit/ml) WAC. First Data. 2017

24 Insulin Mixtures Novolog Mix 70/30-$285.83/10ml vial, $532.20/5 of 3ml FlexPen Humalog Mix 75/25-$264.10/10ml vial, $430.20/5 of 3ml KwikPen, $591.90/3 ml KwikPen-200u/ml Humalog Mix 50/50-$264.10/10ml vial, $430.20/5 of 3ml KwikPen, $591.90/3ml KwikPen-200u/ml Humulin 70/30-$137.90/10 ml vial, $437.25/5 of 3ml KwikPen Novolin 70/30-$137.70/10 ml vial WAC. First Data. 2017

25 Cost Analysis of Amylin Analog
Symlin-Pramlintide- Initial dosing (60 mcg SC prior to major meals)- $546.54/month. Maintenance dosing- $973/month WAC. First Data, 2017.

26 Reduced RX Program Savings Program between CVS Health and Novo Nordisk
Assist patients who are facing high out-of-pocket costs Provides a lower option for diabetes patients to obtain insulin Offers Novolin R, Novolin N and Novolin 70/30 at cost of $25 per vial Patients present card at any of the more than 67,000 participating pharmacies nationwide in the CVS Caremark Network Program starts 5/10/2017 Phone Number for patients

27 Questions


Download ppt "Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for."

Similar presentations


Ads by Google